The Institute for Clinical and Economic Review (ICER) on Wednesday, Jan. 23, announced a global initiative aimed at creating new, alternative methods for evaluating innovative therapies and recommending value-based pricing benchmarks.
According to a press release, the organization will work with a range of stakeholders and groups, including the National Institute for Health and Care Excellence and the Canadian Agency for Drugs and Technologies in Health.
“Patients and those who care for them eagerly anticipate the coming wave of treatments that may cure a wide range of illnesses,” ICER President Steven Pearson said in a statement. “The science is undeniably exciting. But when these treatments are first launched, which is when pricing and coverage decisions have to be made, the evidence on the long-term value of these treatments may be extremely limited.”
ICER is accepting public input for a number of methodological questions from which it aims to receive “ideas and guidance.” Comments must be submitted by 5 p.m. EST Feb. 20.
To read the full press release on ICER’s website, click here.
